Schroeder Brett A, Kohli Karan, O'Malley Ryan B, Kim Theresa S, Jones Robin L, Pierce Robert H, Pollack Seth M
Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, WA, USA.
Department of Medicine, Virginia Mason Medical Center, Seattle, WA, USA.
Oncoimmunology. 2020 Jan 13;9(1):1710064. doi: 10.1080/2162402X.2019.1710064. eCollection 2020.
Gastrointestinal stromal tumor (GIST) is a devastating disease, especially in the setting of metastasis. The natural progression of GIST has been significantly altered by the development of small molecule tyrosine kinase inhibitors (TKIs), including imatinib, sunitinib, and regorafenib, all of which are FDA approved. However, TKIs are not always well-tolerated, and the refractory disease continues to be a problem. For these reasons, alternative treatments are needed. In this report, we discuss a patient with metastatic wild-type (WT) GIST refractory to multiple TKIs, but with a durable clinical response to the anti-programmed cell death protein 1 (PD-1) antibody, nivolumab. This report suggests that continued research evaluating checkpoint inhibitors in GIST is warranted.
胃肠道间质瘤（GIST）是一种严重的疾病，尤其是在发生转移的情况下。小分子酪氨酸激酶抑制剂（TKIs）的出现显著改变了GIST的自然病程，其中包括伊马替尼、舒尼替尼和瑞戈非尼，所有这些药物均已获得美国食品药品监督管理局（FDA）的批准。然而，TKIs并非总是能被很好地耐受，难治性疾病仍然是一个问题。基于这些原因，需要其他治疗方法。在本报告中，我们讨论了一名转移性野生型（WT）GIST患者，该患者对多种TKIs耐药，但对抗程序性细胞死亡蛋白1（PD-1）抗体纳武单抗有持久的临床反应。本报告表明，有必要继续开展评估GIST中检查点抑制剂的研究。
Zotero 插件
